Sanofi SA (SAN)
Euronext Paris · France · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 74.12 |
|---|---|
| 52-week range | 69.75 – 91.15 |
| Return, 1 month / 3 months | +1.4% / −2.9% |
| Return, 1 year / 3 years | −9.6% / −13.4% |
| Trend | Below its 200-day average |
| RSI (14) | 56 |
| Volatility (1 year) | 22.6% |
| Worst drawdown (1 year) | -18.3% |
| Average daily value traded | 141.80M EUR |
| Dividend yield | 5.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Sanofi is a pharmaceutical company based in Paris, France. It develops and supplies prescription medicines, vaccines and consumer healthcare products, serving patients, doctors, hospitals and health systems in Europe, the United States and other markets around the world. Its activities span several therapeutic areas, including immunology, rare diseases and general medicines, alongside a vaccines business and a portfolio of over-the-counter health products sold through pharmacies and retailers.
On this site Sanofi SA appears as a stock on the Euronext Paris (France), code SAN, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Sanofi SA (SAN) trades on the Euronext Paris in France. It last closed at EUR 74.12 on 23 October 2026.
Its price-based Market X-Ray is 74 out of 100 (a strong price profile), ranking 60 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 9.6% and over the last three months it fell 2.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 68 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -1.3% | ||
| From 52-week high | -18.0% | ||
| Momentum | 56 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -2.9% | ||
| 6-month return | -4.3% | ||
| 12-month return, skipping the last month | -10.9% | ||
| Stability (higher is calmer) | 85 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 22.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -18.3% | ||
| Liquidity | 99 · Strong | Trades actively. | |
| Average daily value traded | 141.80M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 67 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 5.6% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +3.0% |
|---|---|
| 1 month | +1.4% |
| 3 months | −2.9% |
| 6 months | −4.3% |
| 1 year | −9.6% |
| 3 years | −13.4% |
| 5 years | +7.9% |
Signals
| 50-day / 200-day average | 74.28 / 75.13 |
|---|---|
| Golden / death cross (60 days) | Death, 18 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.54 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 5 May 2026 | EUR 4.1200 |
| 12 May 2025 | EUR 3.9200 |
| 13 May 2024 | EUR 3.7600 |
| 30 May 2023 | EUR 3.5600 |
| 6 May 2022 | EUR 3.3300 |
| 5 May 2021 | EUR 3.1826 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.